google-site-verification: googlec7193c3de77668c9.html

Tag Archives: Texas

VT3989 continues to show promising early results in patients with advanced mesothelioma

[ Key trial data from study of VT3989. Credit: The University of Texas MD Anderson Cancer Center The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The …

Read More »

Recent Comments